Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Position Raised by Verition Fund Management LLC

Verition Fund Management LLC raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 35.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,042 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,652 shares during the period. Verition Fund Management LLC’s holdings in Collegium Pharmaceutical were worth $543,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Gladius Capital Management LP bought a new position in Collegium Pharmaceutical in the 2nd quarter worth about $32,000. nVerses Capital LLC lifted its holdings in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,600 shares during the period. GAMMA Investing LLC increased its stake in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares during the period. CWM LLC boosted its holdings in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares in the last quarter. Finally, AXA S.A. acquired a new position in shares of Collegium Pharmaceutical during the second quarter valued at approximately $209,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on COLL shares. HC Wainwright upped their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Piper Sandler restated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Insider Buying and Selling

In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This represents a 15.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $30.42 on Thursday. Collegium Pharmaceutical, Inc. has a 52 week low of $27.41 and a 52 week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market capitalization of $981.05 million, a PE ratio of 13.11 and a beta of 0.80. The company’s 50 day moving average price is $33.67 and its 200 day moving average price is $34.43.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.